- Home
- STRO vs AVIR Comparison
STRO vs AVIR Comparison
Compare STRO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | AVIR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.8M | 429.1M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STRO | AVIR |
|---|---|---|
| Price | $14.88 | $5.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $31.33 | $10.00 |
| AVG Volume (30 Days) | ★ 253.7K | 216.2K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | N/A | ★ N/A |
| Revenue | $38,419,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $2.78 |
| 52 Week High | $43.85 | $6.45 |
Technical Indicators
Market Signals| Indicator | STRO | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 20.09 | 48.40 |
| Support Level | $12.85 | $5.13 |
| Resistance Level | $17.33 | $5.79 |
| Average True Range (ATR) | 1.08 | 0.20 |
| MACD | -0.31 | -0.06 |
| Stochastic Oscillator | 1.10 | 25.56 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.